In 2014, a clinical study on anti-MSLN CAR T cells modified with mRNA for the short-term expression of CAR was reported.101 In this report, the antitumor effect and safety of CAR T-MSLN were suggested in 1 patient with malignant pleural MPM and 1 patient with malignant PC. This evidence concerns the gene MSLN and cancer.